Holen Sie sich die Stockscreener-App
37.06
0.96%
-0.36
Handel nachbörslich:
37.06
Schlusskurs vom Vortag:
$37.42
Offen:
$36.97
24-Stunden-Volumen:
1.89M
Relative Volume:
0.91
Marktkapitalisierung:
$7.64B
Einnahmen:
$2.10B
Nettoeinkommen (Verlust:
$402.17M
KGV:
19.15
EPS:
1.9357
Netto-Cashflow:
$403.87M
1W Leistung:
+1.04%
1M Leistung:
+9.97%
6M Leistung:
-18.05%
1J Leistung:
-21.80%
1-Tages-Spanne:
$36.80
$37.22
1-Wochen-Bereich:
$36.23
$37.78
52-Wochen-Spanne:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Firmenname
Qiagen Nv
Sektor
Branche
Telefon
-
Adresse
-
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
37.06 | 7.64B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
469.34 | 174.42B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
180.10 | 127.47B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.88 | 44.24B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
129.84 | 36.67B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
355.53 | 34.91B | 3.77B | 449.25M | 240.68M | 7.8556 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2026-03-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-22 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-06-24 | Eingeleitet | Barclays | Overweight |
| 2025-04-04 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | Hochstufung | Jefferies | Hold → Buy |
| 2024-10-17 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-06-27 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-07 | Hochstufung | Goldman | Neutral → Buy |
| 2023-09-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-01-18 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-10-14 | Eingeleitet | Redburn | Buy |
| 2021-07-14 | Herabstufung | Kepler | Buy → Hold |
| 2021-06-03 | Eingeleitet | Goldman | Neutral |
| 2020-10-06 | Fortgesetzt | BofA Securities | Buy |
| 2020-09-28 | Hochstufung | Kepler | Hold → Buy |
| 2020-08-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-17 | Hochstufung | Berenberg | Hold → Buy |
| 2020-08-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-08-14 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | Herabstufung | Berenberg | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-12-26 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-11-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-11-14 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2019-11-14 | Hochstufung | Kepler | Reduce → Hold |
| 2019-10-17 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | Herabstufung | Kepler | Hold → Reduce |
| 2019-10-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-10-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2019-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Qiagen Nv Aktie (QGEN) Neueste Nachrichten
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen N.V. Stock (NL0012169213): Sector Check On Diagnostics Player - AD HOC NEWS
Qiagen N.V. Stock: In focus after the latest verified market update - AD HOC NEWS
A Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75 - GuruFocus
Qiagen N.V. stock (NL0012169213): focus on molecular diagnostics and steady demand drivers - AD HOC NEWS
Former AdvaMedDx Board Chair Joins Bruker’s Governing Body - Medical Product Outsourcing
Qiagen N.V. stock (NL0012169213): Diagnostics player stays in focus after latest quarterly update - AD HOC NEWS
How Qiagen N.v. (QGEN) Affects Rotational Strategy Timing - Stock Traders Daily
Qiagen N.V. stock (NL0012169213): Diagnostic specialist updates investors after recent earnings - AD HOC NEWS
Evaluating Qiagen (NYSE:QGEN) After New Bundibugyo Ebolavirus Digital PCR Assays Catch Investor Attention - Sahm
Qiagen N.V. Common Shares (NY: QGEN - FinancialContent
Goldman Sachs Discloses 3.14% Voting Stake in QIAGEN - TipRanks
UBS reveals 3.04% voting stake in Qiagen after AFM filing - TipRanks
Qiagen reports 2.75% voting stake in its shares held by UBS Group - TipRanks
MFS reports 12.45M-share, 6.0% stake in QGEN (NYSE: QGEN) - Stock Titan
Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QIAGEN Business Breakdown and Growth Drivers for 2026 - qz.com
Is Qiagen’s New Bundibugyo Assays Strategy Quietly Reframing Its Infectious Disease Tools Story (QGEN)? - Sahm
Is It Too Late to Buy Qiagen NV (QGEN) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
AlphaValue/Baader Europe Cuts Qiagen Price Target, Estimates Post FY26 Guidance Change - 富途牛牛
LVIP MFS International Growth Fund's Qiagen NV(LTS:0RLT) Holding History - GuruFocus
Qiagen N.V. stock (NL0012169213): Legal probe and Jefferies conference keep shares in focus - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Shares in focus after Jefferies conference appearance and law firm - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V.QGEN - Hastings Tribune
Qiagen N.V. stock (NL0012169213): Deutsche Bank reiterates Buy rating with USD 43 target - AD HOC NEWS
Qiagen (QGEN) Q1 2026 Earnings Transcript - AOL.com
QIAGEN NV : Deutsche Bank keeps its Buy rating - marketscreener.com
Qiagen N.V. (QGEN) Presents at Deutsche Bank German Corporate ConferenceSlideshow (NYSE:QGEN) 2026-06-01 - Seeking Alpha
Evaluating Qiagen (QGEN) Valuation After Recent Short Term Share Price Recovery - Yahoo Finance
Qiagen N.V. (QGEN) Stock Analysis: Healthcare Innovator With Nearly 20% Upside Potential - DirectorsTalk Interviews
Qiagen N.V. stock (NL0012169213): steady after Q1 2026 update while analysts refine outlook - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): shares steady after Q1 2026 update and ownership shift - AD HOC NEWS
UBS Discloses 2.45% Stake in Qiagen via AFM Notification - The Globe and Mail
Bank of America Discloses 3.15% Voting Stake in Qiagen - The Globe and Mail
Legal & General Group Plc Sells 40,221 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. stock (NL0012169213): UBS stake disclosure and AFM voting rights notice keep insider own - AD HOC NEWS
QIAGEN’s Outlook Reset: Can Digital PCR And Sample Tech Offset QuantiFERON Weakness? - Smartkarma
Qiagen N.V. stock (NL0012169213): New Ebola research assays in focus as valuation metrics come into - AD HOC NEWS
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss? - TradingView
Qiagen N.V. stock (NL0012169213): Diagnostics group under scrutiny after investor investigation upda - AD HOC NEWS
Qiagen NV Bolsters Bundibugyo Ebola Research - Devdiscourse
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak - BioSpace
U.S. Sets Up Ebola Quarantine in Kenya - Devdiscourse
Qiagen N.V. stock (NL0012169213): Diagnostics specialist in focus after latest earnings - AD HOC NEWS
Deutsche Bank Maintains Qiagen NV(QGEN.US) With Buy Rating - 富途牛牛
QIAGEN NV : Buy rating from Deutsche Bank - marketscreener.com
Qiagen N.V. stock (NL0012169213): diagnostics specialist in focus after recent business updates - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Diagnostics player in focus after latest quarterly update - AD HOC NEWS
Finanzdaten der Qiagen Nv-Aktie (QGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.38%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):